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Abstract
Objective To assess the evidence on the validity and
responsiveness of five commonly used preference-based
instruments, the EQ-5D, SF-6D, HUI3, 15D and AQoL, by
undertaking a review of reviews.
Methods Four databases were investigated using a strategy
refined through a highly sensitive filter for systematic
reviews. References were screened and a search for grey
literature was performed. Identified citations were scruti-
nized against pre-defined eligibility criteria and data were
extracted using a customized extraction template. Evidence
on known group validity, convergent validity and respon-
siveness was extracted and reviewed by narrative synthesis.
Quality of the included reviews was assessed using a
modified version of the AMSTAR checklist.
Results Thirty reviews were included, sixteen of which
were of excellent or good quality. The body of evidence,
covering more than 180 studies, was heavily skewed
towards EQ-5D, with significantly fewer studies investi-
gating HUI3 and SF-6D, and very few the 15D and AQoL.
There was also lack of head-to-head comparisons between
GPBMs and the tests reported by the reviews were often
weak. Where there was evidence, EQ-5D, SF-6D, HUI3,
15D and AQoL seemed generally valid and responsive
instruments, although not for all conditions. Evidence was
not consistently reported across reviews.
Conclusions Although generally valid, EQ-5D, SF-6D and
HUI3 suffer from some problems and perform inconsis-
tently in some populations. The lack of head-to-head
comparisons and the poor reporting impedes the compar-
ative assessment of the performance of GPBMs. This
highlights the need for large comparative studies designed
to test instruments’ performance.
Keywords Preference based measures  Psychometric
properties  Quality of life  Review
JEL Classification I
Introduction
Cost utility analysis (CUA) is increasingly used to inform
health policy on whether new interventions should be made
available within a healthcare system. In CUA, benefits are
measured in quality adjusted life years (QALYs) using an
index that combines the length of life and the health related
quality of life (HRQoL) of patients [1]. HRQoL is esti-
mated using preference-based measures (PBMs).
A limited number of generic PBMs (GPBMs) dominate
the literature [2], and these are the EQ-5D, the SF-6D, the
Health Utility Index mark 3 (HUI3), the Assessment of
Quality of Life (AQoL) and the 15 Dimensions (15D) [3].
Their main advantage is, at least theoretically, the ability to
produce values comparable across all interventions and
diseases, therefore resulting in a common currency for
health technology assessment. However, these instruments
differ in terms of the size and content of their descriptive
systems, the valuation methods and the populations used to
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value the health states [3], often generating substantially
different utility values [4]. Differences in the size and
content of the descriptive systems may limit the appropri-
ateness of GPBMs in certain populations, while differences
in the valuation methods and the populations used to value
health states limits comparability between measures
[1, 5, 6]. Given this variability between instruments, a key
issue in the conduct and use of CUAs is the selection of
instrument for measuring health state utility values. On the
one side, the selected measure should be appropriate for the
group of patients being examined in the evaluation in terms
of its ability to detect meaningful changes; on the other
side, the selected measure should ensure comparability
between studies within the conditions and/or between
conditions (depending on jurisdiction), to ensure an effi-
cient allocation of resources.
To help address the selection of measures, there is a
growing body of literature investigating the empirical
validity (construct validity) and responsiveness of GPBMs
in different populations. Validity has been defined as how
well an instrument measures what it is intended to measure
[7, 8], while responsiveness is a related concept on the
ability of a measure to detect changes in health when these
have occurred [9]. There is an increasing number of sys-
tematic reviews summarizing the validity and responsive-
ness of GPBMs in either a specific population or for a
specific GPBM. However, it is difficult to draw conclusions
regarding the performance of these measures, as the evi-
dence is piecemeal. This study seeks to address the gap by
providing a summary of the overall construct validity and
responsiveness of five GPBMs, including the coverage and
nature of the evidence in different conditions based on
existing reviews, through an overview of reviews.
Overviews of reviews compile evidence from multiple
reviews into a single accessible and usable document,
offering a ‘‘friendly front end’’ platform for decision
makers [10]. The steps required for conducting an over-
view of reviews are similar to those used in systematic
reviews and are described in detail in Higgins and Green
[10]. Broadly, these involve designing a searching strategy,
screening the references obtained using a set of pre-defined
eligibility criteria, assessing the reviews in terms of their
quality and summarizing their evidence in an easily
accessible format. The methods used in this overview of
reviews are described in detail below.
Methods
An overview of reviews was undertaken. Consistent with
the Cochrane collaboration guidelines [10] all phases of
this study were planned and summarized in an overview
protocol (available from authors). Formal guidance on
reporting of overviews of systematic reviews does not
exist, but whenever possible, we followed the 27-item
checklist covering important information needed in
reporting systematic reviews and meta-analysis of the
preferred reporting items for systematic reviews and meta-
analysis (PRISMA) [11].
Search strategy and study identification
A search strategy was developed to identify systematic
reviews on the validity and responsiveness of the five most
commonly used GPBMs for adults, across all disease
classes. The search combined free text and controlled
vocabulary words, including ‘‘quality of life’’, ‘‘patient
reported outcome’’, ‘‘preference based instrument’’, ‘‘psy-
chometric characteristic’’, ‘‘EQ-5D’’, ‘‘SF-6D’’, ‘‘HUI3’’,
‘‘AQoL’’ and ‘‘15D’’, all with spelling variations, acro-
nyms and related terms (Appendix I). A highly sensitive
searching filter for systematic reviews and meta-analysis
developed by the information services team of the Cana-
dian Agency for Drugs and Technologies in Health was
used to refine the search [12], which was not limited by
date or language restrictions. Medline, Embase, Cochrane
Library and Scharr HUD electronic databases were inves-
tigated. In addition, references of the included reviews
were screened and a complementary search on Google
Scholar was performed.
Identified citations (both published and grey literature)
were assessed against the following set of pre-defined eli-
gibility criteria. Reports were eligible for inclusion if they
were reviews, they examined construct validity or
responsiveness of at least one GPBM, their main focus was
on an adult population (defined as C18 years old) and they
summarized results reporting information at the study level
(either in the review text, tables or appendix). Systematic
reviews were excluded if they reported results only in
aggregate form, if they only examined psychometric
characteristics other than construct validity or responsive-
ness (e.g. reliability or face validity), if they only included
translations of a GPBM, if they were not in English or if
they were only in a poster presentation.
Quality assessment of the reviews
Quality was assessed using a modified eight question ver-
sion of the AMSTAR checklist for systematic reviews [13]
with items weighted for importance based on the research
team views (See Appendix Table 2). Questions on the
‘‘comprehensiveness of the literature search’’, the ‘‘pres-
ence of a quality assessment tool’’ and the ‘‘use of quality
scores to formulate conclusions’’ were assigned two points
as they were considered essential for the correct identifi-
cation and assessment of quality of studies included in
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reviews. ‘‘Characteristics of the included studies’’ was
assigned 1.5 points, as these might significantly impact on
the results. ‘‘Presence of duplicate data selection and
extraction’’ and ‘‘double blinding’’ (although rarely used in
systematic reviews of psychometric evidence) were
assigned a score of one since they strengthen the reliability
of the selection process. Questions on providing an a priori
design, which minimizes the chance of results being
changed once searches have being completed, a list of
included studies and conflicts of interest were given a
weight of 0.5 as these were considered to have less of an
impact on reviews of psychometric studies. Questions in
AMSTAR on the ‘‘methods used to combine findings’’, the
‘‘likelihood of publication bias’’ and the ‘‘status of publi-
cation used as an inclusion criterion’’ were excluded
because they were considered irrelevant for systematic
reviews of measures’ psychometric performance.
The resulting checklist has a minimum score of 0 and a
maximum score of 10. As a way to categorize the quality of
systematic reviews, arbitrary cut-offs were assigned, con-
sidering them of excellent quality if they received a score
C7.5, of good quality if they received a score C5 and of
poor quality with a score\5. Scores for both the original
and the modified checklists are provided in the Appendix
Table 3.
Data extraction
A customized extraction template was designed and piloted
on 5 reviews. Information on review characteristics (e.g.
review objectives, number of studies included, disease
classes investigated, condition examined) and details of the
psychometric assessments undertaken were extracted. In
the case of a review published in several places, then the
article with the most up-to-date data was used, supple-
mented by additional evidence contained in the other
sources. When different reviews included the same study,
the most complete data for that study were extracted,
supplemented by the evidence contained in the other
review and presented in the results for only one of the two
reviews to avoid double counting of studies.
Assessment of findings
Validity
Validity of an instrument should ideally be assessed by
comparing it to a gold standard measure of the construct of
interest. Where a gold standard or criterion does not exist,
psychometricians use indirect indicators of validity [14]. One
indicator is the ability of an instrument to distinguish between
groups known or thought to differ in the trait or behaviour,
such as defining groups by severity of condition or patients vs
general population. Care should be paid in using traits that are
relevant for GPBM assessment, as not all traits used to test
HRQoL are relevant for testing GPBMs (for a detailed dis-
cussion of traits relevant for GPBM assessment please see
Brazier et al. [14]).Assessmentofwhether ornot knowngroup
validity is evident can then be based on whether those with
poorer health also have lower utility scores, using appropriate
tests to assess whether these differences are statistically sig-
nificant (e.g. t-tests) and important in magnitude (e.g. using
standardized effect sizes (SES), which is the difference in the
scores divided by the pooled standard deviation).
Another indicator is convergent validity, which examines
the extent towhich twomeasures of the sameor similar concept
agree with each other, for example by using correlations. The
magnitude of the correlation is used to judge the extent towhich
GPBMs are related to the comparison measure.
Responsiveness
Responsiveness focuses on a measure’s ability to reflect
changes that have occurred in health [9, 14], such as by
comparing patients before and after a successful treatment.
Change is usually assessed based on whether differences in
utility scores are statistically significant and their stan-
dardized magnitudes coherent with the change that has
occurred, using standardized effect sizes (SES) or stan-
dardized response means (SRMs) (i.e. the mean change
divided by the standard deviation of the change scores).
Criteria for psychometric assessment
Criteria are required to judge whether measures meet the
psychometric properties being assessed. Cohen’s criteria have
been used in this overview [15]. Correlations are very strong if
[0.6; strong between 0.5 and 0.6;moderate between 0.49 and
0.3; and weak if B0.29 [15]. Moderate to very strong corre-
lations were taken as an indicator of convergent validity. SES
and SRMs were judged as large if they wereC0.80; moderate
between 0.50 and 0.79; and small between 0.2 and 0.49 [15].
Moderate to large ESs and SRMs were taken as a sign of
construct validity or responsiveness. Statistical significance
was also considered as evidence to support known group
validity and responsiveness. These criteria only provide
indicative guidance on the psychometric characteristics of an
instrument. Judgements must also be made based on the
quality of studies included and the characteristics of the
indirect indicators that are used.
Reporting
Evidence is presented in summary tables by measure and
condition and reviewed by narrative synthesis. In the sum-
mary tables, symbols are used to identify where evidence
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supports validity or responsiveness (4), suggests poor
validity or responsiveness (7), is mixed (±), which indicates
some supporting evidence and some against, inconclusive (/
), when evidence is lacking, e.g. data too sparse, or NRwhen
the measure is not reported in the review. Conditions are
grouped using the international classification of diseases
[16]. AQoL 8D and 15D results are only presented in the text
due to the limited evidence found.
Results
A total of 2216 potentially relevant articles were identified
after removing duplicates. Title and abstract screening
excluded 1661 and 465 records, respectively, and full text
screening excluded an additional 63. Online search and
reference screening found 3 reviews that had not been
detected by database searches. Consequently, 30 reviews
were included [17–46]. Figure 1 summarizes the selection
process. A list of included and excluded reviews is pro-
vided in Appendix Tables 4 and 5.
Characteristics of the included reviews
The number of studies included in the reviews varied sig-
nificantly,1 from five [38] to 122 [39]. Most reviews
Record identified
n=2844
Records removed n=63
Of which:
• Reviews on paediatric 
populations n=2
• Reviews not reporting 
validity or responsiveness 
estimates n=15
• Poster presentations n=8
• Reviews not investigating at 
least one preference based 
instrument n=14
• Other study design n=19
• Studies in language other 
than English, Portuguese or 
Italian n=2
• Not possible to retrieve n=1
• Reviews on adaptation of 
instruments n=1
• Reviews not reporting 
results for individual studies 
n=1Systematic reviews included
n=30
Online 
search/reference 
screening
Systematic reviews
included
n=3
Duplicates removed
n=628
Title screening
n=2216
Records removed
n=1661
Abstract screening
n=555
Records removed
n=465
Full text screening
n=90
Fig. 1 Flow diagram
1 Not all the studies included in the reviews were relevant to the
research question investigated in this overview. However, this
overview draws on more than 180 studies included in the 30 reviews.
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included a mix of randomized clinical trials (RCTs), cross-
sectional, cohort and longitudinal studies, or a mix of other
experimental and/or observational designs, apart from
Devine et al. [38] which focused on longitudinal studies
and Holloway et al. [45] which focused on RCTs. One
review by Bansback et al. [43] included only economic
evaluations. Table 1 summarizes the main characteristics
of the included reviews.
Quality of included reviews
Two reviews [24, 40] received an assessment of excellent
quality and 14 of good quality [17–21, 23, 25–28, 30, 32,
33, 36]. The remaining 14 reviews received a poor quality
assessment [22, 29, 31, 34, 35, 37–39, 41–46]. The main
reason for poor quality was that reviews did not assess the
quality of the included papers themselves and, conse-
quently, did not consider scientific quality appropriately
in drawing conclusions. Five reviews received an
AMSTAR modified score below 3, with four of them
reporting a literature search that was not considered
comprehensive (i.e. terms were not derived paying
attention to synonyms, acronyms and related terms for the
building blocks of the research question) [29, 37, 42, 44]
and none of these performed a double-blind study selec-
tion [29, 37, 42, 44, 46].
Breadth and depth of the evidence
Twenty-nine reviews reported information for the EQ-5D,
twelve for the SF-6D, eight for the HUI3, two for the 15D
and three for the AQoL 8 dimensions.
EQ-5D psychometric characteristics were presented for
conditions across 16 ICD classes of disease codes
(Table 2). Two reviews reported EQ-5D characteristics in a
class not specified (i.e. aesthetic surgery in Ching [44] and
older population in Haywood [36]). SF-6D psychometric
performance was reported for conditions related to 9
classes of disease, HUI3 to 7 classes, and 15 D and AQoL
only to 2 classes of disease.
The amount of evidence in relation to the psychometric
assessment of validity and responsiveness within condi-
tions varied substantially, with some reviews reporting
multiple psychometric analysis results and others focusing
on a single type of assessment. Overall there was much less
evidence available for measures other than the EQ-5D.
Type of evidence
Known groups testing Of the 180 studies included in the
systematic reviews that reported known groups validity, 77
used comparisons based on severity traits although two
studies did not use all the potential severity levels [29, 34].
For the other studies comparisons were based on patients
versus general population (44 studies), different types of
diseases or disorders (15 studies), groups defined by an
HRQoL instrument (7 studies), numbers of diseases/dis-
orders (4 studies) and patients with or without complica-
tions (3 studies). Comparisons were also based on other
groups such as discharged and not discharged patients (21
studies). Nine studies used groups that were considered
inappropriate for testing GPBM validity, like age, educa-
tion, different country cohorts and income. Most studies
assessed known groups based on utility scores, but seven
reviews [21, 24–26, 28, 30, 32] reported results for
unscored dimensions of the instruments.
Convergent validity Correlations with other measures
were reported in 135 studies, 38 of which used a non-
preference-based HRQoL measure, 32 a direct utility
measure (e.g. TTO), 27 a symptom or severity measure, 18
a functional status measure, 9 another GPBM and 14 did
not specify the measure used.
Responsiveness Reviews reported 172 studies on GPBM
responsiveness, most of which (n = 124) were based on
comparing patients before and after a successful treatment,
with 112 of these reporting statistically significant differ-
ences, 8 reporting SESs, 2 reporting SRMs and 2 not
reporting the method employed. Comparisons were also
based on patient groups receiving different treatments
(n = 38; 32 reporting statistical significance and 6 report-
ing SESs), and patients reporting an improved health state
(n = 6; 3 reporting SESs and 3 reporting SRMs). Four did
not specify the groups used, but reported SRMs.
Performance of instruments by condition
The overwhelming majority of evidence in type 1 [23] and
2 [23, 42] diabetes mellitus showed that EQ-5D possessed
good discrimination between severity groups, correlated
moderately to strongly with other HRQoL instruments and
reported changes consistent with expectations after
patients’ treatment. Little evidence was found for the SF-
6D, and this was mixed.
The review on diseases of the skin and subcutaneous
tissues [28] (including psoriasis, acne, eczema and leg
ulcers) presented results supporting EQ-5D validity and
responsiveness, with only 2 out of 27 studies reporting
evidence against the measure’s validity, which were weak
correlations and lower SRMs for EQ-5D compared to other
measures.
Two systematic reviews investigated COPD and asthma
[29, 31], suggesting that the EQ-5D is generally valid
based on known group comparisons of severity and
patients/general population groups and correlations
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Table 1 Characteristics of the included reviews
Disease area Report Condition/
population
Quality PBM/s
included
Aims and objectives Number of
reports
(number of
studies)*
Autoimmune
system
Castelino
[34]
Systemic lupus
erythematosus
Poor EQ-5D
SF-6D
To evaluate the development and psychometric
properties of health related quality of life
measures used in adults with systemic lupus
erythematosus
13 (13)
Holloway
[42]
Systemic lupus
erythematosus
Poor EQ-5D To create a conceptual model of the humanistic
and economic burden of systemic lupus
erythematosus and review the patient reported
outcomes used to measure the concept in SLE
clinical trials
68 (68)
Cardiovascular
system
Dyer [31] Heart disease Good EQ-5D
SF-6D
HUI3
To synthesize the evidence on the validity and
reliability of the EQ-5D in studies within the
cardiovascular field; to summarize the EQ-5D
based score reported in studies within the
cardiovascular field; and to attempt to stratify
mean utility scores according to level of disease
severity
66 (66)
Ear Yang [24] Hearing
impairment
Good EQ-5D
SF-6D
HUI3
To assess the reliability, validity and
responsiveness of the EQ-5D, HUI3 and SF-6D
for measuring health related quality of life in
people with hearing impairment
18 (14)
Endocrine,
nutritional and
metabolic
diseases
Janssen [20] Type 2 diabetes Good EQ-5D
SF-6D
15D
To summarize the evidence on the validity,
reliability and responsiveness of the EQ-5D in
studies of diabetes type 2
59 (59)
Speight [39] Type 2 diabetes Poor EQ-5D To clarify the measurement of QoL in terms of
conceptualization, terminology and
psychometric properties, to review the
instruments that have been most frequently used
to assess QoL in diabetes and make
recommendations in how to select measures
appropriately
19 (19)
Eye Tosh [23] Visual
impairment
Good EQ-5D
SF-6D
HUI3
To assess the appropriateness of the EQ-5D, HUI3
and SF-6D in patients with visual disorders due
to the different ways particular conditions affect
HRQoL
31 (31)
Genitourinary
system
Davis and
Wailoo
[18]
Urinary
incontinence
Good EQ-5D
SF-6D
15D
AQoL-8
To assess the appropriateness of the EQ-5D in
people with urinary incontinence
17 (17)
Wu [30] HIV Good EQ-5D To examine the responsiveness of two health
related quality of life measures used in clinical
trials involving HIV infected adults
17 (17)
Gynaecological
problems
Sanghera
[43]
Menorrhagia Poor EQ-5D To review which economic measures have been
used or assessed in menorrhagia and present
criteria for deciding which measure is the most
appropriate
56 (56)
Haematological
problems
Szende [29] Haemophilia Good EQ-5D
HUI3
To review and evaluate the performance of health
related quality of life and other health status
measures used in studies of haemophilia in adult
patients and provide recommendations for future
research
19 (19)
A. P. Finch et al.
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Table 1 continued
Disease area Report Condition/
population
Quality PBM/s
included
Aims and objectives Number of
reports
(number of
studies)*
Musculoskeletal
system
Bansback
[40]
Rheumatoid
arthritis
Poor EQ-5D
SF-6D
HUI3
To review the clinical measures used in
rheumatoid arthritis economic evaluations with
respect to their relevance and sensitivity to
changes in survival, health related quality of life
and costs
22 (22)
DeVine [35] Chronic low
back pain
Poor EQ-5D To determine the correlation of patient reported
pain with physical function and health related
quality of life after spine surgery and the
responsiveness of pain, physical function and
health related quality of life measures after spine
surgery (for chronic low back pain)
5 (5)
Hill [38] Spinal cord
injury
Poor SF-6D To critically review quality of life instruments
used in spinal cord injury
14 (14)
Whitehurst
[33]
Spinal cord
injury
Good SF-6D To review the use of generic preference-based
instruments of health-related quality of life
within the context of spinal cord injury
22 (22)
Mental health Brazier [14] Bipolar
disorder
Good EQ-5D To examine the validity and responsiveness of two
generic preference-based measures of health (the
EQ-5D and SF-6D) and two generic non-
preference-based measures (the SF-36 and SF-
12) in populations with bipolar disorder
22 (22)
Papaioannou
[15]
Personality
disorder
Good EQ-5D To assess the construct validity and
responsiveness of four generic health status
measures in personality disorder
10 (10)
Papaioannou
[16]
Schizophrenia Good EQ-5D
SF-6D
To assess the construct validity and
responsiveness of four generic health status
measures in schizophrenia
33 (33)
Peasgood
[17]
Depression/
anxiety
Good EQ-5D
SF-6D
HUI3
To assess the construct validity and
responsiveness of EQ-5D and SF-6D measures
in depression and anxiety
26 (26)
Hounsome
[32]
Dementia Poor EQ-5D
HUI3
To review evidence relating to the application of
EQ-5D in dementia research and issues
concerning its use
21 (18)
Neoplasm Longworth
[22]
Cancer Good EQ-5D
SF-6D
HUI3
To assess the reliability, validity and
responsiveness of the EQ-5D, HUI3 and SF-6D
for measuring health related quality of life in
cancer
98 (98)
Pickard [28] Cancer Poor EQ-5D To summarize evidence on the validity and
reliability of EQ-5D in cancer
34 (34)
Nervous system Kuspinar and
Mayo [21]
Multiple
sclerosis
Excellent EQ-5D
SF-6D
HUI3
AQoL 8
To summarize the evidence from published
literature on the psychometric properties of
generic utility measures in multiple sclerosis
15 (15)
Nose Linder [37] Acute sinusitis Excellent EQ-5D To identify and compare the performance of
HRQoL instruments or symptom scores for
adults with acute sinusitis
29 (29)
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between the EQ-5D and non-preference-based HRQoL
measures. Results for responsiveness were mixed, with two
studies reporting weak SRMs of the measure, one study
strong SRMs and four showing changes in the expected
direction using SESs and statistical significance. The only
comparative study across GPBMs reported poor correla-
tions between EQ-5D and SF-6D.
One review each investigated the performance of the
EQ-5D in urinary incontinence [21] and HIV [33]. There
was evidence of validity and responsiveness in urinary
incontinence [21] with five studies supporting discrimina-
tive validity based on severity levels and type of urinary
incontinence, seven reporting moderate to strong correla-
tions with HRQoL and symptom and severity measures,
and five showing differences in health status from baseline
to follow-up and between treatment arms. Two studies
reported mixed results, one showing that the EQ-5D dis-
tinguished between some types of urinary incontinences
but not others, and the other that the EQ-5D detected
treatment differences only for some groups of patients,
where other measures registered changes for all treatment
groups. Two studies had inconclusive results for conver-
gent validity as they did not specify the strength of corre-
lations between measures. One study reported results for
other GPBMs, supporting SF-6D, 15D and AQoL known
group validity based on the assessment of severity traits. In
HIV [33] responsiveness of the EQ-5D was weak, showing
generally small before and after treatment SESs in the
presence of moderate or large ESs for the comparator
measures. The only study investigating construct validity
reported a good ability of the measure to discriminate
between known groups.
The EQ-5D appeared generally valid and responsive in a
number of cancers [25, 31] (including lung, breast, cervi-
cal, colon, kidney, liver cancer and leukemia) although
limitations were found in some studies. Twenty-five of the
31 studies examining known group differences showed that
EQ-5D distinguished between cancer severities,
patients/general population and groups with different types
of cancer; 12 of the 17 studies examining convergent
validity reported moderate to strong correlations with
direct utility measures, HRQoL measures and functional
status measures; and 29 of 43 studies examining respon-
siveness showed that the measure detected changes
between treatment arms and from baseline to follow-up
that were consistent with those of comparator measures. A
significant amount of evidence supported HUI3 psycho-
metric characteristics [25, 31] with 8 studies out of 11
showing good discriminative ability in distinguishing
between severity levels, type of cancer and cancer
patients/general population, 4 studies out of 7 reporting
good convergence with functional status measures and 8
Table 1 continued
Disease area Report Condition/
population
Quality PBM/s
included
Aims and objectives Number of
reports
(number of
studies)*
Others Ching [41] Aesthetic
surgery
Poor EQ-5D To critically review the present literature to
identify the appropriate instruments to assess
outcomes in aesthetic surgery
43 (not clear)
Derrett [19] Injuries Poor EQ-5D To describe EQ-5D administration, summarize its
reliability and validity and report its outcomes in
injuries
44 (41)
Haywood
[36]
Older patients Poor EQ-5D
AQoL 8
To review the evidence relating to the
measurement properties of multi-item generic
patient or self-assessed measures of health in
older people
122 (122)
Respiratory
system
Petrillo [26] Asthma/COPD Poor EQ-5D To present and discuss the empirical evidence on
the validity of generic multi-attribute utility
instruments within the COPD population
22 (22)
Pickard [27] Asthma/COPD Good EQ-5D
SF-6D
To synthesize literature on the validity and
reliability of EQ-5D use in studies of asthma and
COPD, and estimate EQ-5D utility scores
associated with different stages of the disease
18 (18)
Skin and
subcutaneous
tissues
Yang [25] Skin condition Good EQ-5D To assess the reliability, validity and
responsiveness of the EQ-5D, HUI3 and SF-6D
for measuring health related quality of life in
skin conditions
16 (16)
* Not all the studies included in the reviews were relevant to the research question investigated in this overview. However, this overview draws
on more than 150 studies included in the 30 reviews
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studies out of 10 a good ability to detect changes from
baseline and between treatment arms. Only two studies
reported information for the SF-6D. In one, the measure
was not able to detect differences between cancer patients
and the general population. In another, the measure cor-
related appropriately with a cancer HRQoL questionnaire.
Very few comparative studies were reported between the
investigated GPBMs, and these do not clarify which per-
forms better.
The EQ-5D showed a mixed performance in cardiovas-
cular diseases [34] (including coronary heart disease, cere-
brovascular disease, hypertension and heart failure).Although
many studies supported the instrument’s convergent validity
with other GPBMs, HRQoL measures and functional status
measures, and its ability to distinguish known groups based on
severities of the conditions and type of conditions, two studies
showed poor correlations with HRQoL measures, three had
problems in distinguishing between patients and the general
population, eight failed to detect statistically significant
changes at follow-up and one failed to show differences
between treatment arms. Three comparative studies were
reported between the EQ-5D and SF-6D, the EQ-5D and
HUI3, and the EQ-5D, SF-6D and HUI3. In two of them,
correlation between the EQ-5D and SF-6D, and between the
EQ-5D, HUI3 and SF 36 were generally poor. The third
comparative study presented moderate to strong correlations
between the three instruments.
The EQ-5D performance in visual disorders [26] (in-
cluding macular degeneration, glaucoma, conjunctivitis,
diabetic retinopathy and others) was generally mixed.
Known groups showed generally poor or mixed validity
using severity groups, and generally good validity using
patients versus general population groups. Mixed evidence
was also reported for convergent validity, with the instru-
ment correlating moderately to strongly with clinical
measures only in four of the nine studies that investigated
the property. There was mixed and limited evidence for
EQ-5D responsiveness, with one study reporting in sup-
port, one against and one with mixed evidence for the
measure’s responsiveness. All these studies used tests of
statistical significance before and after treatment. The
HUI3 appeared to be valid although the evidence was
limited. Two studies reported a good ability of the measure
to distinguish known groups based on the severity of the
condition and on patients/general population. Another
study reported moderate to strong correlations with func-
tional status measures. A fourth study showed that the
HUI3 was able to detect statistically significant changes
between treatment arms [26]. Only two studies reported on
the SF-6D characteristics, and these showed that the
measure performed better than the EQ-5D [26].
EQ-5D performance has been reviewed in only one
condition of the nervous system [24], multiple sclerosis,T
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with three studies supporting the instrument’s convergent
validity and three reporting weak to moderate correlations
with other HRQoL measures. Substantial evidence against
the instrument’s ability to distinguish between severity
groups was found, with two studies reporting that the
measure distinguished only between some severity levels
but not others (mixed evidence), and two showing the
measure was not able to detect health status differences in
any of the severity levels. Evidence for the SF-6D, HUI3
and AQoL was limited, but in support of the measure’s
performance [24], with two studies reporting moderate to
strong convergence of the SF-6D with HRQoL measures,
two showing good discriminative ability of the HUI3
between severity groups, strong correlations of the measure
with other HRQoL instruments and two showing good
discriminative ability of the AQoL, with the assessment
being based on severity levels.
The EQ-5D performance in hearing impairments [27]
was poor, with only two studies out of the seven supporting
validity and responsiveness, one reporting moderate to
strong correlations with other GPBMs and the other
reporting statistically significant changes of score before
and after treatment. The HUI3 showed a better perfor-
mance, with all known group assessments but one in favour
of the instrument’s validity (based on severity traits) and
most of the responsiveness tests showing an ability to
detect changes in health status before and after treatment
[27]. Although few comparative studies were found, all
these suggested that the HUI3 performs better than the EQ-
5D in hearing impairment.
Five reviews investigated the performance of the EQ-5D
in mental health [17–20, 35], and all but the one on
depression and anxiety showed that the instrument suffered
from problems. Three studies showed low correlations
between the EQ-5D and HRQoL measures in dementia;
four had low correlations between the EQ-5D and the time
trade-off, standard gamble and symptom specific measures
in schizophrenia; two had low correlations between the
EQ-5D and other measures (not specified) in bipolar dis-
order; and two had low to moderate correlations between
the EQ-5D and symptom and severity measures in per-
sonality disorders. Evidence against the measure’s validity
was also found for known groups in personality disorders
and bipolar disorder, with one study showing poor dis-
crimination between groups based on different types of
personality disorders, and another poor discrimination
between severity levels of bipolar disorder. Convergent
validity, known groups and responsiveness results for the
SF-6D and HUI3 supported the instruments’ psychometric
characteristics, with the exception of an SF-6D known
group test that showed mixed results in depression (dis-
criminating only between some groups but not others) [20],
although the evidence base was smaller.
Four systematic reviews reported evidence on EQ-5D
and SF-6D psychometric characteristics in musculoskeletal
diseases [36, 38, 41, 43]. One study reported good con-
vergence for the EQ-5D with another HRQoL measure in
rheumatoid arthritis, while another had inconclusive results
in chronic low back pain, with data being too sparse to
assess correlations. The SF-6D was seen to have moderate
to strong convergence with an HRQoL measure in
rheumatoid arthritis, but mixed known group results in
spinal cord injuries, with three studies supporting the
instrument’s discriminative ability and four reporting
against it [36].
Evidence for the other ICD disease classes was very
sparsely investigated, including haematological, gynaeco-
logical and autoimmune diseases, and diseases of the nose.
Three reviews investigated injuries, aesthetic surgery and
older populations, but evidence was extremely limited,
although the few studies available were generally in sup-
port of the GPBMs’ psychometric characteristics
[21, 31, 36, 38, 39, 43–45].
Discussion
The aim of this overview of reviews was to summarize the
evidence on the construct validity and responsiveness of
five GPBMs, the EQ-5D, SF-6D, HUI3, AQoL and 15D in
terms of the size, quality and nature of the evidence across
different conditions, and to determine whether it is possible
to draw conclusions about their relative performance. A
systematic overview of reviews was undertaken that yiel-
ded 30 systematic reviews, which included more than 180
studies.
Size and coverage of the evidence
The body of evidence was heavily skewed towards EQ-5D,
with significantly fewer systematic reviews investigating
HUI3 and SF-6D, and almost none investigating 15D and
AQoL. Furthermore, the number of conditions covered was
limited, even for EQ-5D. There were also limitations in the
psychometric assessment that was reported. For example,
some studies only reported convergent validity, or reported
comparisons with only one other indicator. This limits the
conclusions that can be drawn from the evidence, partic-
ularly in terms of comparability between different GPBMs.
Quality, nature and reporting of evidence
Many of the reviews received an AMSTAR modified score
of poor quality mainly because they did not assess the
quality of the studies they included and consequently the
impact of this on their synthesized results. In the presence
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of discordant results between studies, quality assessment
can help in the interpretation and synthesis of evidence, for
example by giving greater weight to more robust reports.
Reviews reporteddifferent types of evidence for eachof the
two indicators of validity and responsiveness, such as known
groups being defined by severity, number of diseases/disor-
ders or patient versus general population, and treated them as
equally informative. Although this is common practice in
empirical studies, some tests should be considered more
appropriate than others. For example, the trait severity of a
disease may be considered more informative than the trait
number of disease/disorders in known group assessments,
since the ranking of preferences might be ambiguous in the
latter case, e.g. one severe condition might be worse than two
mild ones. Comparing patient and general population scores is
likely to be very crude. Furthermore, the tests often rely on
clinical assessments that may not reflect the HRQoL of
patients or preferences for the states. These aspects needmore
careful consideration in the phases of review analysis and
synthesis, as well as for the design of primary studies.
A number of concerns exist about the way in which
evidence was reported by the included reviews. Few
reviews stated with clarity which thresholds were adopted
in analyzing and summarizing results, making the inter-
pretation of the definitions ‘‘strong’’, ‘‘moderate’’ or
‘‘weak’’ more difficult. It was also common to find out-
comes defined as ‘‘significant’’, and doubts remained as to
whether ‘‘significant’’ meant statistically significant or
significant in size, or both. Some known group tests based
on severity of the condition reported only part of the range
of possible severity levels. This significantly weakens the
value of the evidence produced.
Performance of instruments
Despite the lack of evidence and standardization across the
reviews or studies included in psychometric assessment,
some broad conclusions can be drawn from this overview of
reviews. Where evidence was available, it often supported
the GPBM’s performance. EQ-5D appeared valid and
responsive in conditions of the skin, respiratory, genitouri-
nary, endocrine, nutritional and metabolic diseases, and for
the majority of cancers where there was evidence; SF-6D
was found to be valid and responsive in mental health and in
diseases of the eye, the nervous and the genitourinary sys-
tems; HUI3 showed good validity and responsiveness in
cancer, diseases of the eye, the ear, the nervous system and
mental health; AQoL presented good psychometric charac-
teristics in musculoskeletal and genitourinary conditions,
and 15D in genitourinary, diabetes, nutritional andmetabolic
diseases. However, any attempt to compare the instruments
is limited by a lack of head-to-head comparisons and the little
evidence available on all GPBMs except EQ-5D.
There was also evidence of lack of appropriateness of
GPBMs in some conditions. EQ-5D was found to perform
poorly in hearing impairments, multiple sclerosis, personality
disorders, schizophrenia and dementia, and reported mixed
results in visual disorders and in some cancers. SF-6D showed
inconsistencies in its ability to converge with other measures
in cardiovascular and respiratory diseases and to discriminate
between groups in neoplasms, while HUI3 reported mixed
results for some subpopulations of neoplasms.
Most of the evidence that was used in the reviews relied
on studies that used existing datasets, but this provides
limited answers when investigating GPBMs’ comparative
performance and it highlights the importance of designing
bespoke comparative studies for this purpose. There are a
few examples of these, including two large and two smaller
studies where five instruments were investigated [47], and
the more recent Multi Instrument Comparison (MIC) pro-
ject [48], that compared a number of GPBMs and other
measures across different conditions. This evidence shows
that convergence between GPBMs is generally moderate to
large, but that differences in scores are mostly driven by
the different constructs covered by the their descriptive
systems. The presence or absence of dimensions covering
constructs relevant to a specific condition/disease area
might serve as an explanation for the lack of validity and
responsiveness noticed in some disease areas for the
investigated GPBMs.
Limitations of the overview
This overview of reviews has some important limitations.
Psychometric properties of GPBMs in some conditions
may have been missed because of the lack of a systematic
review for those conditions. In addition, this overview has
been limited by the poor reporting of some reviews/studies.
This overview focused on the five most widely used gen-
eric GPBMs, but there are other methods for obtaining
health state utility values which were not covered, such as
condition specific PBMs, bespoke vignettes or direct val-
uations of patients’ health states [1]. These alternatives
may provide an important source of evidence for reim-
bursement decisions, particularly where the existing gen-
eric measures do not appear to perform well. However,
these have not been included in the current overview of
reviews as GPBMs are the preferred option for CUA of
health care interventions.
Conclusions
Whenever evidence is available, it often supports the per-
formance of GPBMs. However, the breadth and depth of
this evidence is inconsistent between ICD disease classes,
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conditions, instruments and type of assessment. Indeed
there is often no evidence at all, or what is available is
severely limited in nature and quality, and rarely enables
direct comparisons across measures. This highlights the
need for large comparative studies designed to test the
performance of instruments, therefore producing evidence
that is equivalent in breadth, depth and quality for all
GPBMs. In addition, more rigorous reporting of GPBM
psychometric studies and reviews is recommended.
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